Barnaby Pickering
Managing Editor, Custom Content
Barnaby began reporting on health and life sciences topics in 2021 after graduating with a master's degree in biomedical engineering from University College London, during which he learned in detail how medical devices are invented, developed, approved and ultimately commercialized.
In the time since, Barnaby has covered topics ranging from diabetes and diagnostics to neuro and nanotechnology, all with a focus on the interplay between major stakeholder groups: patients, companies, regulators, and investors. Barnaby is an avid conference attender, and frequently moderates panel discussions focusing on both commercial and regulatory issues.
Barnaby lives in Frome, Somerset, but is originally from Surrey. When allowed by the English weather, he enjoys running, cycling and rock climbing.
Latest From Barnaby Pickering
LSX Nordic 2024: Strategics Offer Tips On Landing A Partnership Or Acquisition
At this year’s LSX Nordic conference, experts from Baxter, Philips and Novo Nordisk described key attributes they look for when selecting companies for partnerships or acquisitions and provided advice to founders on how and when to start positioning their start-ups for such opportunities.
Genetic Analysis Leaders On Gut Microbiota Testing, Pharma Connections And Direct-To-Consumer Scene
Genetic Analysis CEO Ronny Hermansen and Christina Casén, senior VP of clinical and medical affairs, discuss the company’s polymerase chain reaction (PCR)-based approach to gut microbiota profiling versus DNA sequencing, competitive landscape including DTC, and opportunities for supporting pharma R&D and assessing drug treatment success.
Genetic Analysis Leaders On Gut Microbiota Testing, Pharma Connections And Direct-To-Consumer Scene
Genetic Analysis CEO Ronny Hermansen and Christina Casén, senior VP of clinical and medical affairs, discuss the company’s polymerase chain reaction (PCR)-based approach to gut microbiota profiling versus DNA sequencing, competitive landscape, and opportunities for supporting pharma R&D and assessing drug treatment success.
J&J Versus Auris: Robotics Fallout With Big Implications For M&A
J&J’s “pants down” moment with Auris could permanently change how medtech M&A is conducted. Build-to-buy arrangements, which leave companies’ destinies in the hands of their owners, are likely to replace current earn-out models.
2024’s Medtech Venture Investment Climate Warmer Than 2023. Will It Last?
Venture investment in medtech seems to be improving, particularly in diagnostics and tools, and down-value rounds have decreased. However, interest rates are still much higher than three years ago, and many tech investors continue to avoid the health care sector as a whole.
Entering Estonia: To Build Bigger Castles, You Need A Better Sandbox
Estonia is hoping to create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.